Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 1.00 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.74 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.66 |
| ▸ | CPA3 | P15088 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11936654 | 1.00 | NAALAD2 (1.00) | NAALAD2FOLH1RIMKLACPA3 | |
| SCHEMBL18180178 | 0.88 | NAALAD2 (0.78) | NAALAD2FOLH1 | |
| SCHEMBL19969196 | 0.88 | NAALAD2 (0.78) | NAALAD2FOLH1 | |
| SCHEMBL9965331 | 0.88 | NAALAD2 (1.00) | NAALAD2FOLH1RIMKLA | |
| SCHEMBL4316981 | 0.88 | NAALAD2 (1.00) | NAALAD2FOLH1RIMKLA | |
| SCHEMBL13515316 | 0.88 | NAALAD2 (1.00) | NAALAD2FOLH1RIMKLA | |
| SCHEMBL14116846 | 0.87 | NAALAD2 (0.77) | NAALAD2FOLH1CPA3 | |
| SCHEMBL11941426 | 0.87 | NAALAD2 (0.77) | NAALAD2FOLH1CPA3 | |
| SCHEMBL11977625 | 0.87 | NAALAD2 (0.77) | NAALAD2FOLH1RIMKLACPA3 | |
| SCHEMBL4317844 | 0.87 | NAALAD2 (0.77) | NAALAD2FOLH1RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | NAALAD2 3/4885FOLH1 1/4885RIMKLA 197/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | NAALAD2 7/4885FOLH1 5/4885RIMKLA 6/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | NAALAD2 7/4885FOLH1 5/4885RIMKLA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.